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ARTICLE
Population Pharmacokinetics of Methylphenidate in
Healthy Adults Emphasizing Novel and Known Effects of
Several Carboxylesterase 1 (CES1) Variants
YK Lyauk1,∗, C Stage2, TK Bergmann3,4, L Ferrero-Milliani5, D Bjerre5, R Thomsen6, KP Dalhoff7, HB Rasmussen5 and G Jürgens1
The aim of this study was to identify demographic and genetic factors that significantly affect methylphenidate (MPH) phar-
macokinetics (PK), and may help explain interindividual variability and further increase the safety of MPH. d-MPH plasma
concentrations, demographic covariates, and carboxylesterase 1 (CES1) genotypes were gathered from 122 healthy adults and
analyzed using nonlinear mixed effects modeling. The structural model that best described the data was a two-compartment
disposition model with absorption transit compartments. Novel effects of rs115629050 and CES1 diplotypes, as well as previ-
ously reported effects of rs71647871 and body weight, were included in the final model. Assessment of the independent and
combined effect of CES1 covariates identified several specific risk factors that may result in severely increased d-MPH plasma
exposure.
Clin Transl Sci (2016) 9, 337–345; doi:10.1111/cts.12423; published online on 18 October 2016.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Large unexplained IIV is observed in the PK of MPH. The
CES1 SNP rs71647871 GA has been reported to substan-
tially increase MPH plasma exposure. The effect of CES1
diplotypes on MPH metabolism is unknown.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ First, this study developed a d-MPH population PK
model that included the effects ofCES1 variants and demo-
graphic covariates. Second, the model was used to assess
the independent and combined effects of covariates on
d-MPH plasma exposure.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
✔ This analysis reveals the effects of rs115629050 TG and
CES1 diplotypes on d-MPH PK. It also confirms the effect
of rs71647871 GA and body weight. Additionally, it illus-
trates the considerable d-MPH plasma exposure increases
caused by the independent or combined presence of CES1
variants.
HOW THIS MIGHT CHANGE CLINICAL PHARMACOL-
OGY OR TRANSLATIONAL SCIENCE
✔ These findings may eventually contribute to the quan-
titative guidance of individual dosing recommendations
based on specific CES1 variants or variant combinations,
and lead to increased safety with MPH.
Methylphenidate (MPH), a central nervous system stimulant,
is the most commonly prescribed drug for the treatment
of patients with attention deficit hyperactive disorder.1,2 It
is also prescribed for other conditions, such as narcolepsy
in adults as well as depression in the elderly and patients
with advanced illness.3–5 A significant increase in MPH pre-
scription has occurred in developed countries over recent
years.6–8
The pharmacokinetics (PK) of MPH have been reported
to display large unexplained interindividual variability (IIV)9–11
and certain studies indicate a 30-fold difference in MPH
serum concentrations 1 h postdose12 and up to a sevenfold
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difference inmaximal concentrations.13 The study ofMPHPK
is relevant from a clinical perspective due to significant corre-
lation betweenMPH concentration and clinical response.14,15
Furthermore, a linear relationship betweenMPHdose and the
development of adverse effects has been reported,16 and,
hence, MPH-related adverse effects may be concentration-
dependent. Adverse effects during MPH treatment are com-
mon and are in the majority of cases categorized as mild
to moderate.17 They include insomnia, anorexia, anxiety,16
as well as cardiovascular effects in terms of increases in
heart rate and blood pressure.18,19 However, due to their
sympathomimetic activity,20 case reports of serious adverse
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effects, such as sudden cardiac death, stroke, myocardial
infarction, and hypertension, have raised concerns regarding
stimulants’ cardiovascular safety.21,22 It has been hypothe-
sized that pharmacogenetic factors may predispose certain
individuals to a higher risk of harmful adverse effects dur-
ing treatment and, hence, further research that may lead to
increased safety with MPH has been encouraged.17
Human metabolism of MPH is predominantly mediated
by carboxylesterase 1 (CES1), a serine esterase, which de-
esterifies MPH to ritalinic acid in the liver.23 Approximately
80% of orally administered MPH is recovered in urine as rital-
inic acid, whereas minor metabolites of MPH or ritalinic acid
each account for a nonsignificant amount.24 In recent years,
differences in CES1 have been found to affect the PK of sev-
eral drugs metabolized by CES1, in particular MPH.13,25–27
A nonsynonymous single nucleotide polymorphism (SNP),
rs71647871 GA (p.Gly143Glu) with a reported frequency of
3.7% in Caucasians, has been identified to significantly influ-
enceMPH PK.13 It has been found to cause a reduction in the
catalytic activity of CES1; consequently, MPH metabolism
is reduced and substantially elevated MPH plasma expo-
sure is observed in carriers.13 Apart from the aforementioned,
no studies have yet been able to identify other CES1 SNPs
that impact MPH PK. Considering the crucial role of CES1 in
MPH metabolism, it is plausible that additional CES1 SNPs
that impact MPH PK may exist. In addition to CES1 SNPs,
CES1 gene structure has also been found to influence the
PK of CES1-metabolized drugs. A study involving the CES1-
metabolized compound, irinotecan, has shown the presence
of CES1A2 to have a significant effect on its PK,28 and it is
therefore of interest to investigate the impact of CES1A2 on
MPH metabolism. CES1A2 is a hybrid gene with a reported
allele frequency of 14.4% in Caucasians consisting of the
upstream portion of the nonfunctional pseudogene CES1P1
(also referred to as CES1A3) and a duplicated segment of
CES1.29 The latter is commonly designated CES1A1 to dis-
tinguish it from CES1A2. One of three possible CES1 diplo-
types can be present in a given individual: two CES1A1
and two CES1P1, which is the most frequent; two CES1A1,
one CES1P1, and one CES1A2; or two CES1A1 and two
CES1A2.30
Until now, studies that have reported an association
between CES1 variants and MPH PK have done so while
focusing on one variant at the time through noncompartmen-
tal methods, and have therefore not considered any potential
combined variant effect. This is of interest to investigate
given thatCES1 variants resulting in altered drug metabolism
may be due to SNPs and potentially structural CES1 dif-
ferences. Use of population PK modeling for assessing the
impact of genetics on drug PK holds several advantages
compared with the noncompartmental approach. These
include the ability to perform a simultaneous analysis of the
effects of several demographic and/or genetic covariates,
as well as clinical trial simulation, which may illustrate the
risk associated with a particular effect or combination of
effects.31 Furthermore, in the presence of nonlinearity or
variability in drug bioavailability, model-based phenotype
allows a higher probability to detect SNP effects than
other phenotypes.32 Presently, population-based analyses
of MPH are few9,33,34 and none have, to this date, included
CES1 variants as covariates, despite their reported effect
on MPH metabolism13 and the metabolism of other CES1-
metabolized compounds.28 Therefore, the aim of this work
is to build on recent CES1 pharmacogenetic findings and
develop an MPH population PK model, which (i) identifies
significant effects of demographic covariates as well as
different types of CES1 variants on PK parameters and their
IIV, and (ii) can determine the independent and potential
combined effects of covariates on MPH plasma exposure.
METHODS
PK data from two previously conducted clinical studies
(NCT02135263 and NCT02147535) at Bispebjerg Hospi-
tal, Copenhagen, Denmark, were aggregated for analy-
sis. Both study protocols were reviewed and approved by
an ethical review board. The studies were conducted in
accordance with all applicable regulatory and Good Clinical
Practice guidelines and followed the ethical principles orig-
inating in the Declaration of Helsinki. All participants were
fasting overnight and MPH was administered 1 h following a
standardized breakfast. Two participants did not receive the
standard meal due to lactose intolerance and a food delivery
issue. Study I involved 44 healthy adult volunteers who were
administered a single dose of 10 mg MPH (Ritalin; Novar-
tis, Basel, Switzerland). Plasma samples from each subject
were collected predose and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10,
24, and 33 h postdose. Study II involved 78 healthy adult
volunteers who were administered a single dose of 10 mg
MPH (Ritalin), followed by the collection of a single plasma
sample from each subject 3 h postdose. All subjects were
Caucasians and their demographic characteristics are pre-
sented in detail in Supplementary Table S1. All participants
were CES1 genotyped using DNA extracted from saliva sam-
ples. Details regarding the genetic analysis are presented in
the Supplementary Material, along with the genetic charac-
teristics of participants in the two studies (Supplementary
Table S2).
d-MPH and l-MPH plasma concentration analysis is
described in the Supplementary Material. Population PK
modeling was performed using nonlinearmixed-effectsmod-
eling software (NONMEM, version 7.3; ICON Development
Solutions, Ellicott City, MD) and the first-order conditional
estimation with interaction method. In total, 503 d-MPH
plasma concentrations collected from 122 healthy adults
were analyzed and handling of data below the quantifica-
tion limit is presented in the SupplementaryMaterial. Model
development procedure and criteria are presented in detail in
the Supplementary Material. The following covariates were
investigated: body weight, body mass index, gender, and a
total of nine CES1A1 SNPs that result in nonsynonymous
amino acid substitutions in CES1, as well as CES1 diplo-
types. Covariate model development was performed using a
stepwise procedure with a forward inclusion p value < 0.05
(objective function value [OFV] decrease > 3.841, 1 degree
of freedom) and a backward elimination p value < 0.005
(OFV increase > 7.879, 1 degree of freedom). In order to
explore the effect of CES1 variants in which subjects in the
studied population presented missing genotype data, meth-
ods for handling missing covariate data were considered. As
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Figure 1 Schematic diagram of the structural d-methylphenidate (MPH) pharmacokinetic model along with model-incorporated covari-
ates. d-MPH passes through three transit compartments (TCs) into an absorption compartment, where it is absorbed into the cen-
tral compartment and distributed to the peripheral compartment. d-MPH undergoes elimination from the central compartment to
d-ritalinic acid (CL/F). ktr is the transit rate constant and is defined as (number of TCs + 1) divided by mean transit time. ka is the
absorption rate constant. Vdcentral/F and Vdperipheral/F represent apparent central and peripheral volumes of distribution, respectively. Q/F
is the apparent inter-compartmental clearance. Dotted circles and arrows indicate covariates and the parameters they affect, respectively.
CES1, carboxylesterase 1.
a first step, the nature of the missing data were investigated.
It was examined whether the missing data were missing
completely at random, missing at random,35 or missing not at
random.36 Based on the nature of the missing data, a method
for handling missing data was chosen. Permutation test-
ing was performed for each included covariate to determine
actual significance levels and account for type I error (Sup-
plementary Material). The individual contribution of each
incorporated covariate on IIV reduction and explanation of
parametric variability was also assessed (Supplementary
Material).
The final fixed-effect and variability parameter estimates
of the model were used to perform Monte-Carlo simulations
(n = 5,000) for each model-included covariate and assess
its independent effect on d-MPH plasma exposure together
with the 95% prediction interval, following oral administra-
tion of a 10 mg MPH dose. The same procedure was used
to determine the effect of physiologically plausible covariate
combinations. A change of ± 30% in d-MPH plasma expo-
sure compared with a reference population was considered
clinically significant in this study. Last, the model was used
to obtain a preliminary estimate of the incidence of specific
covariates and plausible simultaneous combination in indi-
viduals within a large virtual population (n = 100,000) and
their relation to changes in d-MPH plasma exposure.
RESULTS
The final d-MPH PK model was a two-compartment model
with absorption transit compartments and first-order elim-
ination from the central compartment. The parameter
estimation process and covariance step both converged suc-
cessfully using the first-order conditional estimation method
with interaction. Three significant digits were requested in
the parameter estimates. The structural model along with PK
parameters and covariates that influence them are shown
in Figure 1. The final parameter estimates are shown in
Table 1, along with nonparametric 95% confidence inter-
vals obtained through bootstrapping. The estimated num-
ber of transit compartments was originally 3.05 (data not
shown) but was fixed to the value of 3.0 in subsequent mod-
els to aid model stability and successful convergence. No
significant changes to the model fit and parameter estimates
were observed doing so. IIV was estimated for apparent oral
clearance (CL/F), central volume of distribution (Vdcentral/F),
and mean transit time (MTT) in a full variance-covariance
matrix, containing both diagonal and nondiagonal elements.
A proportional error model was used to describe unexplained
residual variability.
The final model included allometrically scaled body weight
using a fixed value of 0.75 for CL/F and apparent inter-
compartmental clearance (Q/F) and 1 for Vdcentral/F and
apparent peripheral volume of distribution (Vdperipheral/F).
Estimation of allometric exponents for these parameters was
evaluated; however, no significant change in OFV or parame-
ter estimates was obtained. The effects of the CES1 genetic
covariates rs71647871, rs115629050, and CES1 diplotypes
were included on CL/F. Genotype information regarding
CES1 diplotypes, rs71647871, and rs115629050 was miss-
ing in 0.8%, 5%, and 42%, respectively, of the total stud-
ied population. Missing data were considered as being miss-
ing not at random and was handled using the EXTRA (or
EST) method.37,38 Gender was included on MTT due to the
improvement of model fit assessed through decrease of OFV
and improvement of visual diagnostics. Incorporation of the
aforementioned covariates reduced the OFV by 104.3 points,
reduced unexplained CL/F IIV by 15.0%, and increased the
proportion of explained CL/F IIV to total CL/F IIV from zero
www.wileyonlinelibrary/cts
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Table 1 Final d-MPH population PK model parameter estimates
Model parameter NONMEM estimate (RSE%) Bootstrap estimate (RSE%) Nonparametric (95% CI)
Structural model
θ1: MTT (/h) 0.505 (13.7) 0.521 (16.3) (0.371–0.707)
θ2: No. of transit compartments (fixed) 3 – –
θ3: ka (/h) 0.418 (18.8) 0.430 (134.0) (0.370–1.304)
θ4: CL/F (L/h) 233.0 (3.6) 231.7 (4.5) (214.0–251.8)
θ5: Vdcentral/F (L) 97.6 (28.6) 101.8 (63.7) (47.6–288.7)
θ6: Q/F (L/h) 70.1 (47.8) 74.3 (38.7) (49.9–175.3)
θ7: Vdperipheral/F (L) 252 (30.9) 260.7 (64.5) (198.2–453.2)
Covariate effects
θ8: Female gender on MTT 0.925 (44.3) 0.852 (42.7) (0.297–1.831)
θ9: rs71647871 (GA) on CL/F −0.587 (6.9) −0.585 (8.8) (−0.677 to −0.473)
θ10: Missing data rs71647871 on CL/F −0.157 (46.9) −0.161 (54.6) (−0.330 to −0.00164)
θ11: One CES1A2 on CL/F −0.182 (31.9) −0.184 (36.8) (−0.307 to −0.0475)
θ12: Two CES1A2 on CL/F −0.410 (22.5) −0.408 (25.6) (−0.583 to −0.192)
θ13: Missing data CES1A diplotype on CL/F −0.535 (9.0) −0.535 (11.3) (−0.663 to −0.440)
θ14: rs115629050 (TG) on CL/F −0.403 (26.1) −0.399 (31.4) (−0.714 to −0.180)
θ15: Missing data rs115629050 on CL/F 0.090 (79.6) 0.0913 (86.8) (−0.0623 to 0.262)
Weight exponent on CL/F (fixed) 0.75 – –
Weight exponent on Vdcentral/F (fixed) 1 – –
Weight exponent on Q/F (fixed) 0.75 – –
Weight exponent on Vdperipheral/F (fixed) 1 – –
IIV (%CV)
MTT 62.1 (27.7) 60.8 (29.3) (43.1–78.8)
CL/F 21.6 (15.4) 21.0 (17.6) (17.3–24.4)
Vdcentral/F 90.1 (27.1) 87.7 (38.5) (54.7–123.5)
Residual variability
Proportional error 0.184 (9.6) 0.181 (10.2) (0.144–0.218)
CES1, carboxylesterase 1; CI, confidence interval; CL/F, apparent oral clearance; CV, coefficient of variation; IIV, interindividual variability; MPH, methylphenidate;
MTT, mean transit time; PK, pharmacokinetic; Q/F, apparent intercompartmental clearance; RSE, relative standard error; Vdcentral/F, central volume of distribution.
ka, absorption rate constant; NONMEM, non-linear mixed effects modeling software. 2,000 nonparametric bootstrap CI were generated.
to 50.1% compared with the base model without covariates.
OFV drop, CL/F IIV reduction, and proportion of explained
CL/F IIV to total CL/F IIV increase for the stepwise addition of
each covariate is shown in Table 2. The two model-included
CES1A1 SNPs, rs71647871 and rs115629050, were not cor-
related as observed in a linkage disequilibrium analysis (Sup-
plementary Figure S1) and both could therefore be incorpo-
rated in the model. Permutation testing results for the model-
inclusion of covariates are shown in Supplementary Table
S3.
The equations that describe the typical values of the final
model parameters are:
MTT = θ1 ∗ (1 + Gender ∗ θ8 )
CL
F
= θ4 ∗ (1 + rs71647871 ∗ θ9 )
∗ (1 + One CES1A2 ∗ θ11 )
∗(1 + Two CES1A2 ∗ θ12 )
∗ (1 + rs115629050 ∗ θ14 )
∗
(
WT
70
)0.75
Vdcentral/F = θ5 ∗
(
WT
70
)
Q/F = θ6 ∗
(
WT
70
)0.75
Vdperipheral/F = θ7 ∗
(
WT
70
)
The variables Gender, rs71647871, rs115629050, one
CES1A2, and two CES1A2 are equal to zero and take on the
value of one for individuals that possess the gender or geno-
type reported in Table 1. WT represents the body weight of
the individual subject. Goodness of fit plots and a visual pre-
dictive check for the final model are shown in Figures 2 and
3, respectively.
Results of the Monte-Carlo simulations highlighting the
independent effects of each model-incorporated covariate
on d-MPH plasma exposure are shown in Figure 4. Signif-
icant increases in d-MPH plasma exposure compared with
a wild-type reference population were observed for carri-
ers of 71647871 GA (143%), two CES1A2 (70%), as well
as rs115629050 TG (68%), whereas a minor increase was
seen for carriers of one CES1A2 (22%). Populations consist-
ing of 50 kg as well as 100 kg individuals were simulated to
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Table 2 Effect of each included covariate on the objective function value, decrease in unexplained d-MPH apparent clearance (CL/F) IIV, and increase in explained
d-MPH CL/F IIV
Model OFV decrease Unexplained CL/F IIV decrease (% CV) Explained CL/F IIV increase (%)
Model A: Base model + body weight 20.068 1.6 10.2
Model B: Model A + rs71647871 38.874 8.6 19.3
Model C: Model B + rs115629050 15.888 2.3 10.5
Model D: Model C + gender 12.693 0.40 1.5
Final model: Model D + CES1 diplotype 16.820 2.1 8.6
CL/F, apparent oral clearance; CV, coefficient of variation; IIV, interindividual variability; MPH, methylphenidate; OFV, objective function value. Base model repre-
sents the final structural model without covariates. Unexplained CL/F IIV was assessed through NONMEM’s OMEGA output. Explained CL/F IIV was calculated
as explained CL/F IIV divided by total CL/F IIV (total CL/F IIV being the sum of unexplained and explained CL/F IIV and is subject to change during model
development), and explained and total parametric variability estimates were obtained from pvar in Perl-Speaks-NONMEM (PsN).
Figure 2 Diagnostic plots for the final d-methylphenidate (MPH) population pharmacokinetic model. Top left corner: Observed d-MPH
plasma concentrations (DV) vs. population predictions (PRED). Top right corner: Observed d-MPH plasma concentrations (DV) vs. individ-
ual predictions (IPRED). Bottom left corner: Conditionally weighted residuals (CWRES) vs. PRED. Bottom right corner: CWRES vs. time
after dose.
explore the effect of low or high body weight, respectively,
on d-MPH exposure. A 29% d-MPH exposure increase and
24% d-MPH exposure decrease was observed for individu-
als of 50 and 100 kg, respectively. However, differences in
body weight did not alter the effects of the CES1 variants to
a significant extent compared with their independent effects
in 70 kg individuals (Supplementary Table S4 and Supple-
mentary Figure S2).
The simulation results investigating the effect of the phys-
iologically plausible simultaneous presence of two or more
CES1 variants on d-MPH plasma exposure are shown in
Figure 5. Twofold to sevenfold plasma d-MPH exposure
increases resulting from different variant combinations were
observed. In order to estimate the frequency of occurrence
of CES1 variants as well as their plausible combined pres-
ence in individuals, a simulation of a large virtual population
www.wileyonlinelibrary/cts
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Figure 3 Visual predictive check for the final d-methylphenidate
(MPH) population pharmacokinetic model. Solid lines represent
the 5th, 50th, and 95th percentiles of the observed data. Dashed
lines represent the 5th, 50th, and 95th percentiles of the simulated
data. Shaded areas represent 95% confidence intervals around
the 5th, 50th, and 95th percentiles of the simulated data.
Figure 4 Forest plot of the simulated independent effect
of each model-included covariate. Effects are expressed as
d-methylphenidate (MPH) plasma exposure (area under the curve
[AUC]0-inf) relative to a reference population (70-kilogram male
adults, carrying the wild-type carboxylesterase 1 [CES1] variants
rs71647871 GG, rs115629050 GG, and noCES1A2). The indepen-
dent effect of each covariate is investigated, keeping all other char-
acteristics similar to the reference population. Median AUC0-inf,
followed by 95% prediction intervals in brackets are reported for
each population, consisting of 5,000 virtual individuals. Dotted
lines indicate AUC0-inf changes of ± 30%, which was considered
clinically significant in this study.
Figure 5 Forest plot of the physiologically plausible simu-
lated combined effects of model-included covariates. Effects are
expressed as d-methylphenidate (MPH) plasma exposure (area
under the curve [AUC]0-inf) relative to a reference population (70-
kilogram male adults, carrying the wild-type carboxylesterase
1 [CES1] variants rs71647871 GG, rs115629050 GG, and no
CES1A2). The combined effects of each covariate are investigated,
keeping all other characteristics similar to the reference popu-
lation. Median AUC0-inf, followed by 95% prediction intervals in
brackets, are reported for each population, consisting of 5,000 vir-
tual individuals.
(n = 100,000) was performed (Supplementary Tables S5
and S6). It was found that approximately 4.1% of the total
simulated population showed a d-MPH plasma exposure
increase between twofold and threefold while carrying CES1
variants or variant combinations. It is to be noted that 5.4%of
individuals (234 of 4,339 subjects) presenting a plasma expo-
sure increase between two to threefold were carriers of the
wild-type CES1 genotype (Supplementary Table S6). Fur-
thermore, approximately 1.3% of the virtual population con-
sisting of 100,000 individuals showed a larger than threefold
plasma exposure increase while carrying CES1 variants or
combinations. In comparison, only 0.3% of the total sim-
ulated population showed a larger than threefold elevated
d-MPH exposure while carrying the wild-type CES1 geno-
type (Supplementary Table S6). Thus, these results indicate
that a small minority of a given Caucasian population under-
going treatment withMPHmay be predisposed to experience
substantially higher d-MPH plasma exposure owing directly
to specific CES1 variants or variant combinations. Subse-
quently, such patients may potentially have a higher risk of
adverse effects during MPH treatment.
DISCUSSION
This study is the first to examine the population PK of d-MPH
while including effects of both demographic covariates and
CES1 variants. Model-based analyses investigating the PK
Clinical and Translational Science
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of MPH are limited,9,34 and none have included information
concerning CES1.
Rs71647871 GA (p.Gly143Glu) was found to significantly
reduce d-MPH apparent oral CL/F and this is in accor-
dance with previously reported findings.13 Its effect has
also been identified on the PK of several other CES1-
metabolized drugs.25–27 Incorporation of rs71647871 was
found to decrease d-MPH CL/F unexplained IIV and increase
explained CL/F IIV to a greater extent than inclusion of other
covariates. This indicates that rs71647871 is a very impor-
tant covariate in determining MPH PK interindividual differ-
ences. The simulated independent presence of rs71647871
GA resulted in a 2.4-fold increase in d-MPH plasma expo-
sure, and, hence, this variant could potentially be considered
an adverse effect risk factor during MPH treatment.
This study found that rs115629050 TG (p.Ala270Ser) sig-
nificantly reduces d-MPH CL/F and this is, to our knowl-
edge, the first time this has been reported. Model incorpo-
ration of this variant was found to reduce unexplained and
increase explained d-MPH CL/F IIV to a reasonable level
compared with the inclusion of other model-included covari-
ates. Simulations showed that rs115629050 TG resulted in
approximately 68% higher d-MPH plasma exposure in carri-
ers compared with the wild-type genotype. The only current
evidence, which supports the observed effect of thisCES1A1
SNP, are in silico CES1 functional annotation predictions,
performed using different software packages, and a total of
nine different scoring methods (Supplementary Table S7).
For rs115629050 TG, the scores were equal to or greater
than those of rs71647871 GA in six of the nine approaches
(Supplementary Table S8). However, in vitro studies regard-
ing the impact of CES1 variants on a series of CES1-
metabolized angiotensin-converting enzyme inhibitors have
not been able to identify the effect of rs115629050 TG
on drug metabolism.39 These conflicting results may arise
from differences in CES1 affinity to the aforementioned
angiotensin-converting enzyme inhibitors andMPH, resulting
in a lack of effect of rs115629050 TG. Furthermore, it should
be noted that extrapolation of in vitro results to clinical study
observations is difficult. Additional studies need to be per-
formed to confirm the effect of rs115629050 TG on CES1
activity and MPH PK.
CES1 diplotypes were associated with significantly lower
estimates of d-MPH CL/F. Furthermore, model-inclusion
of CES1 diplotypes decreased unexplained and increased
explained d-MPH CL/F IIV to a reasonable level compared
with the other model-included covariates. Simulations indi-
cated that two CES1A2 copies resulted in approximately
70% higher d-MPH plasma exposure in carriers compared
with the wild-type genotype, whereas one CES1A2 copy
yielded an approximately 22% increase. These findings are
in conflict with those from a study with CES1-metabolized
irinotecan, in which presence of CES1A2 resulted in an
increase in systemic clearance.28 Additionally, a clinical PK
study involving oseltamivir found no effect associated with
CES1 diplotypes.40 Therefore, additional studies need to be
performed to confirm the effect of CES1 diplotypes on CES1
activity and MPH PK.
Body weight was not found to alter the observed effects
of model-included CES1 variants to a significant extent.
This may imply that when adjusting dose according to
weight, carriers of plasma exposure-increasing CES1 vari-
ants, included in the current study, may still experience sig-
nificantly increased MPH plasma exposures, and potentially
be in higher risk of adverse effects. A preliminary study inves-
tigating the body weight-based daily dose required for symp-
tom reduction in patients with attention deficit hyperactive
disorder, has shown that significantly lower MPH doses were
needed in patients carrying rs71647871 GA compared with
noncarriers.41 The completion of similar studies focusing on
CES1 variants identified in this study is of interest to establish
the clinical relevance of the findings.
To date, only rs71647871 GA has been reported to have
significant impact on MPH PK,13 yet these findings have
revealed that significant increases in d-MPH exposure may
also occur due to other CES1 variants. Within a large popu-
lation, it is possible for several genetic and/or demographic
covariates to co-occur in individuals. Through simulation,
it was observed that the simultaneous presence of several
different CES1 variants may result in severe increases in
d-MPH plasma exposure, ranging from twofold to seven-
fold. Such elevated exposures may put patients in high risk
of developing adverse effects, which could potentially be
serious as well as sudden. In this context, diagnosed or
undiagnosed preexisting conditions (e.g., congenital heart
disease) may further contribute to the occurrence of such
aforementioned events.17 In adults, a significant increase in
the use of stimulants to treat attention deficit hyperactive
disorder has been observed.42,43 Compared with children,
adult patients may present risk factors that are more preva-
lent (e.g., coronary atherosclerosis, hypertension, smoking,
or concomitant use of other drugs)22 and may, therefore, be
predisposed to a higher risk of serious complications during
treatment. A recent study has indicated a significant increase
in risk of ventricular arrhythmia and sudden death in adults
treated with MPH compared with nonusers, although it was
not possible to determine a causal effect due to lack of a
dose-response relationship.43 However, in light of the cur-
rent study’s findings, it could hypothetically be more appro-
priate to consider a dose-concentration-response relation-
ship, given that individuals with different genotypes may
experience markedly different concentrations with the same
dose. Despite the preliminary low incidence estimate of
CES1 variant combinations that result in substantial expo-
sure increases, it is important to consider the widespread use
of MPH. Hence, the reported variants and combinations have
cause to be taken into clinical consideration, along with the
individual patient’s possible preexisting clinical risk or fam-
ily history. It is important to note, however, that improvement
of clinical outcome as well as cost-effectiveness need to be
evaluated before routine pretreatment screening of patients’
CES1 genotype can be implemented in MPH treatment. Con-
sidering the high cost of genetic sequencing and reported
low incidence estimates of risk factorCES1 variants in a large
population, implementation of CES1 screening is not cur-
rently expected to be cost-effective; however, with evolving
technology and decreasing prices of genetic assays, CES1
screening may be a viable tool in the future. Clinical imple-
mentation of CES1 testing could on the other hand poten-
tially occur in specific cases (e.g., should specific patients
www.wileyonlinelibrary/cts
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exhibit unexpected dose-dependent adverse effects at stan-
dard therapeutic doses). In such cases, CES1 genotyping
could be used as a diagnostic tool to clarify if patients are
carriers of risk factor CES1 variants, and thereby help guide
MPH dose adjustment.
In this study, large amounts of missing data were observed
for several CES1A1 SNPs (Supplementary Table S2). Miss-
ing genotype data were in a large part due to a limitation of
the genetic analysis, which is not able to provide sequence
information downstream exon 5 in CES1A1 if CES1A2 is
present. To the best of our knowledge, no assays currently
exist that can overcome the limitation of the current method.
The high sequence homology among CES1A1, CES1P1, and
CES1A2 renders it difficult to develop methods that can dif-
ferentiate between the three genes. Taking the aforemen-
tioned limitation of the genetic analysis into account, as well
as the proportion of differentmissing genotypes, in this study,
missing data were considered as being missing not at ran-
dom. The EXTRA (or EST) method, which quantifies the effect
of missing covariate data through full maximum likelihood
modeling and adds a parameter for each covariate contain-
ing missing data, was therefore chosen due to its precise
and unbiased parameter estimates when dealing with miss-
ing not at random data, as well as its ease of implementa-
tion in stepwise covariate procedures.37,38 Genotype infor-
mation regarding rs115629050, located in CES1A1 exon 7,
was found to be missing in 42% of the study population,
which was high compared with the amount of missing data
observed in the other final model-included CES1 variants.
However, for low (10%) and high (50%) levels of missing cat-
egorical covariate data, the EXTRA method has been shown
to perform similarly well, yielding estimates of PK param-
eters and covariate effects with adequately low bias and
imprecision.37 Other limitations possibly include that all car-
riers of rs115629050 TG as well as a large part of single
CES1A2 carriers were present in the very sparsely sampled
study II (Supplementary Table S2), and this may have influ-
enced accurate estimation of the effect of these variants on
d-MPH CL/F. When analyzing sparse data containing miss-
ing covariate data, a higher bias/imprecision for the covariate
effect magnitude may be observed.37 This may have impli-
cations for the simulation results in this study, and these
should therefore be viewed as preliminary. However, con-
cerning type I errors associated with final model-inclusion
of these covariates, the actual significance levels for their
exclusion from the final model were found to be lower than
the threshold applied in this study (Supplementary Table
S3). Therefore, rs115629050 and CES1 diplotypes were ulti-
mately kept in the final model. Furthermore, despite hav-
ing applied methods for dealing with missing covariate data,
it cannot be ruled out that the currently reported CES1A
diplotype effect on d-MPH CL/F is caused by the presence
of SNPs downstream CES1A1 exon 5 that affect MPH PK.
Therefore, due to the previously mentioned conflicting find-
ings with other CES1-metabolized drugs, possibly inaccu-
rate/imprecise reported covariate effect magnitude, and pos-
sible presence of unidentifiable CES1A1 SNPs downstream
exon 5 in subjects carrying CES1A2, additional studies are
needed to confirm the effects of rs115629050 TG and CES1
diplotypes on CES1 activity and MPH PK. Last, in light of
the presented results, the need for novel genetic assays that
are able to determine SNPs in all CES1A1 exons yet still dis-
tinguish CES1A1 from CES1A2, is greater than ever before.
Additional study limitations are described in the Supplemen-
tary Material.
To conclude, the presented work has developed a pop-
ulation d-MPH PK model that includes the effects of CES1
variants. Novel effects of CES1 variants on MPH PK were
revealed and require further investigation. This study has
contributed to a better understanding of factors, which may
be determinants of interindividual differences in MPH PK.
Through additional studies, it may also contribute to the
accurate estimation of variability in MPH response, as well
as the risk of adverse effects, which in rare cases may be
serious. Last, the need for novel and more informative CES1
assays has also been made clear.
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